CJC-1295 NO DAC (Mod GRF 1-29) (5mg)

CJC-1295 NO DAC Peptide Overview
CJC-1295, classified as a synthetic peptide and a derivative of natural GHRH hormones, consists of 29 amino acids.⁽²⁾ Recognized as DAC GRF (Drug Affinity Complex Growth hormone Releasing Factor), it is alternatively known as CJC-1295 NO DAC or Modified GRF (1-29). This modified version incorporates four substituted amino groups, strategically designed to enhance the peptide’s stability and protect it from degradation.

The origins of modified growth hormone fragments GRF (1-29) trace back to the early 1980s, proposing that the initial 29 amino acids of the natural growth hormone releasing hormone could encompass all the attributes of the complete 44 amino acid peptide.⁽³⁾ Synthetically engineered growth hormone releasing peptides often face a challenge with a brief half-life. Extensive investigations have led to the development of CJC-1295 (No DAC), aiming to address this concern by purportedly offering a stabilized and prolonged duration of action for the peptide.⁽⁴⁾

CJC-1295 NO DAC Mechanism of Action
The mechanism of action associated with CJC-1295 NO DAC peptide involves an apparent enhancement in growth hormone production. This is achieved by the peptide’s interaction with serum albumin through a free thiol group, leading to the formation of a covalent disulfide bond.⁽⁵⁾ The resulting effect is suggested to stimulate a specific region of the pituitary gland, prompting increased releases of endogenous growth hormone. This mechanism potentially contributes to the maintenance of hormonal equilibrium within the body.

With its unique structural composition featuring four amino acid substitutions, this peptide may showcase heightened bioactivity and increased resilience against proteolytic enzymes. Its covalent binding to albumin is a notable characteristic, and there might also be trace amounts bound to fibrinogen and immunoglobulin G (IgG).⁽⁴⁾ Such interactions could potentially result in elevated plasma levels of growth hormone as well as insulin-like growth factor 1 (IGF-1).

Chemical Makeup
Molecular formula: C152H252N44O42
Molecular weight: 3367.9 g/mol
Other known titles: CJC-1295 Without DAC

Scientific Investigations and Clinical Trials

Growth Hormone Inducers and Growth Hormone-Releasing Hormones
In a specific investigation,⁽⁶⁾ scientists aimed to elucidate the potential effects of growth hormone inducers (GHSs) and growth hormone-releasing hormones (GHRHs) – the hormonal category to which CJC-1295 no DAC peptide is attributed. Various analogs were administered to the study participants, and their physiological responses were closely monitored. The extensive duration of the study led the researchers to hypothesize that these hormones might contribute to enhanced growth rate, increased appetite stimulation, and improvement in lean body mass.

CJC-1295 (No DAC) Peptide and Growth Hormone Secretion Patterns
In the early 2000s,⁽⁷⁾ a clinical investigation was carried out on male participants aged between 20 and 40 years. The participants were randomly assigned to two groups, with one receiving a placebo and the other the CJC-1295 peptide. Blood samples were collected one week before and after the administration of CJC-1295 peptide (or placebo) to assess the patterns of growth hormone secretion. The study’s findings suggested that CJC-1295 led to a 7.5-fold increase in growth hormone pulsatility levels compared to the placebo. These heightened levels showed a gradual elevation throughout the study, persisting even one week after the trial concluded.

In another study, subjects aged between 21 and 61 years were examined in two double-blind trials⁽⁸⁾ over a period of 28 days. Subjects were divided into two groups; one group received a placebo, the other received the peptide. At the end of the first round, it was suggested by the researchers that there appeared to be a dependent increment in the mean plasma growth hormone level by up to 10 folds for more than 6 days and in the levels of IGF-1 concentrations by up to 3 folds for up to 11 days. In the second round, it was suggested that with multiple instances of peptide presence, the mean levels of the growth hormone and IGF-1 appeared to remain above baseline for up to 28 days.

CJC-1295 (No DAC) Peptide and Gastrointestinal Responses
Research involving monkeys⁽⁹⁾ has explored the relationship between GHRH analog peptides, including CJC-1295, and VPAC(1)-R receptors located on the smooth muscles of the gastrointestinal system. The findings hinted at a potential influence on bowel movements through this interaction. However, the precise connections between specific peptides and gastrointestinal responses are still in the investigative phase.

CJC-1295 (No DAC) Peptide and Cardiovascular Effects
Early investigations in rodents⁽¹⁰⁾ have indicated that Modified GRF 1-29 peptide, along with other analogs of GHRH derivatives, may demonstrate potential in enhancing heart rate and supporting cardiac function, especially in the aftermath of a heart attack. Research conducted by NIH⁽¹⁰⁾ suggested that peptides acting as GHRH agonists might contribute to the repair of cardiac tissue and potentially improve ejection fraction rates.

CJC-1295 (No DAC) Peptide and Thyroid Function in Growth Hormone Regulation
A study⁽¹¹⁾ explored the impact of Modified GRF peptides on individuals with primary hypothyroidism undergoing thyroid replacement procedures. Fourteen participants aged between 26 and 60 received GRF peptides before and after thyroid replacement, and subsequent monitoring of growth hormone levels was conducted. The findings indicated that subjects exhibited a more pronounced response to GRF peptide following thyroid replacement compared to the pre-replacement period.

CJC-1295 (No DAC) Peptide and Combinatorial Strategies
CJC-1295 NO DAC is recognized for its extended duration of action among synthetic GHRH peptides, differing from other short-acting counterparts. Consequently, when utilized in combination with other peptides, it holds the potential to prolong specific effects. An example of a commonly employed peptide pairing involves Ipamorelin, a synthetic GHRH pentapeptide. Both Ipamorelin and CJC peptides are believed to share similar mechanisms of action, particularly influencing the anterior pituitary gland and potentially triggering growth hormone secretion.

CJC-1295 peptide is exclusively intended for research and laboratory applications. Prior to placing an order, please thoroughly review and comply with our Terms and Conditions to ensure adherence to research guidelines and ethical practices.